Retatrutide vs TirzepatideThe Comparison You've Seen Is Wrong

Most of what's circulating about retatrutide vs tirzepatide reduces to two claims: retatrutide hits three receptors vs tirzepatide's two, and retatrutide beats tirzepatide for weight loss. The old shorthand was 24% vs 21%; the newer TRIUMPH-4 topline pushes retatrutide higher at 68 weeks. The shorthand still misses the decision you are trying to make.

The "three receptors vs two" framing implies additive pharmacology: one more lever, one more effect. The real difference is that the two drugs were built with different shapes. Tirzepatide is a dual agonist (GLP-1 + GIP) with the best current mix of weight loss, body-composition data, and maintenance practicality. Retatrutide is a triple agonist (GIP + GLP-1 + glucagon) that adds a liver-fat and metabolic-throughput arm tirzepatide does not have.

Retatrutide is not automatically the better drug. It is the sharper tool. Its GIP engagement is much stronger per molecule than tirzepatide's, and it turns on the glucagon receptor. That glucagon arm is the source of the liver-fat story, some thermogenic signal, and the heart-rate / chills / dysesthesia side-effect shape that tirzepatide does not carry.

The ceiling comparison still comes from different trials, not a completed head-to-head. The real decision is phenotype and goal. Tirzepatide is usually the better first tool if it is still working and tolerated. Retatrutide becomes interesting when the problem is a true plateau, liver fat, visceral-fat phenotype, recomp, or tirzepatide's appetite suppression feels too flat for training and daily function.

The entire downstream decision — switching, microdosing, starting from scratch, stepping back because of side effects — lives on the other side of this pharmacokinetic reality. Pick the drug on the misreading and you're choosing between "stronger" and "weaker." Pick it on the real comparison and the choice becomes phenotype, goal, and monitoring burden.

At a Glance

These Are Not Two Versions of the Same Drug

Tirzepatide is a dual agonist: one molecule engaging GIP and GLP-1 receptors at specific engineered potencies. Retatrutide is a triple agonist: one molecule engaging GIP, GLP-1, and glucagon receptors — with every one of those engagements tuned to a different strength than tirzepatide's.

Three asymmetries fall out of this table that matter for every downstream decision.

The GIP arm is where retatrutide separates. Retatrutide turns on the GIP signal earlier and harder than tirzepatide. Much of that GIP signal is already online at low dose; higher doses mainly add more appetite pressure and more glucagon signal rather than a clean increase in GIP benefit.¹

Both drugs softened the GLP-1 arm relative to native, deliberately. GLP-1 at full potency is what makes pure GLP-1 agonists like semaglutide produce severe nausea and food aversion. Tirzepatide softened it more than retatrutide. Both also engage GLP-1R in a way that lets the receptor stay responsive longer under chronic dosing than semaglutide does — part of why both tolerate sustained use better at matched satiety.

Tirzepatide has no glucagon engagement at any dose. Retatrutide does, and it doesn't behave like the other two arms — hepatic effects (liver fat oxidation, visceral fat mobilization) appear at low doses where the heart's pacemaker isn't engaged yet. Cardiovascular and peripheral effects only show up at 4 mg and above.

At low dose (1–2 mg), the glucagon arm is already visible in liver-fat data. In the MASLD substudy, 1 mg produced meaningful liver-fat reduction while heart-rate and peripheral effects were much smaller in the obesity cohort. That does not make low dose harmless; it means the liver signal appears before the full systemic side-effect pattern.

At mid-to-high dose (4–12 mg), the peripheral glucagon signaling comes fully online. Heart-rate elevation appears within weeks, dysesthesia emerges at the top of the range, resting metabolic rate lifts more meaningfully. The same mechanism producing subtle long-term effects at 1 mg produces pronounced faster-onset effects at 8–12 mg.

Comparison frame: retatrutide at microdose is GIP-amplified with quiet but active hepatic glucagon. Retatrutide at max dose carries high GIP engagement plus systemic glucagon. Tirzepatide has neither end of that spectrum.

One molecule, three different pharmacologies across its dose range. This is why retatrutide does not behave like "more tirzepatide" — and why a blanket comparison at top dose misses the real decision surface.

The Four Camps: What Dose Matches What Goal

The weight-loss equivalences across the two drugs collapse into four camps. Each camp answers a specific goal, and each is anchored in the available dose-arm data plus receptor-occupancy modeling.

Two plain readings fall out of the table.

Retatrutide uses meaningfully less drug than tirzepatide at matched weight-loss outcomes. Retatrutide's 2 mg produces roughly what tirzepatide's 4–5 mg does. Retatrutide's 5 mg produces what tirzepatide's 10 mg does. The ratio compresses as dose climbs — at 8 mg reta vs 15 mg tirz, the outputs are similar — but through much of the therapeutic range, retatrutide delivers the same scale outcome from a smaller dose. That does not mean it is easier to tolerate.

Tirzepatide's ceiling sits around 21%; retatrutide's published Phase 2 ceiling was 24.2%, and TRIUMPH-4 topline reached 28.7% at 68 weeks. Both drugs saturate: most of the gain is captured below maximum dose. Tirzepatide's 10 → 15 mg step adds little additional weight loss²; retatrutide's 8 → 12 mg step adds scale loss while bringing more of the glucagon-class side-effect spectrum online. Retatrutide's higher absolute ceiling is real, but it is not free.

Real-world prescribing already reflects this saturation on the tirzepatide side. Across five recent cohorts totaling more than 40,000 users, 56–74% of persistent tirzepatide users sit at sub-10 mg dosing by their sixth prescription, with a modal maintenance dose of 5 mg and measured 6-month weight loss of 11–13% in non-diabetic users.¹⁶ The ladder gets used as a real-world ladder, not a destination.

If you're carrying a lower BMI than the trial cohort, the dose columns shift. The numbers came from trial populations — non-diabetic obesity around 110 kg / BMI 38. For someone leaner, metabolically healthier, using reta for recomp, or cutting from a lower starting weight, the retatrutide column can shift down substantially. That is why 0.25-0.5 mg may be a real protocol for some users, not just a cautious starter. The same rule does not apply as sharply to tirzepatide.

These equivalences hold for weight loss. They don't hold for side effects — and they break entirely for liver fat.

Liver Fat Is a Different Decision

If the goal is weight loss, the four camps above are the decision surface. If the goal is liver fat — MASLD, NAFLD, elevated hepatic fat on imaging, or cardiometabolic risk tied to visceral and hepatic compartments — the decision is different. Different dose, different ceiling, different timeline, different drug.

Retatrutide does a lot more to the liver than tirzepatide does. Direct MRI-PDFF measurement in 98 non-diabetic adults with obesity and ≥10% baseline liver fat captured liver fat reduction at every retatrutide dose⁶:

Three things in this table reshape the retatrutide decision.

Liver fat is mostly a 24-week story, not a 48-week one. At 8 mg, the 24-week liver fat reduction (81.4%) is indistinguishable from the 48-week reduction (81.7%) — 99.6% of the effect is already captured at the halfway point. Weight loss continues through 48 weeks; liver fat does not move much further. The hepatic signal appears to reach the physiological floor (~2.1% absolute liver fat, the UK Biobank median) within the first six months.

8 mg is the effective ceiling for liver fat. At 24 weeks, retatrutide 8 mg produces 81.4% reduction; 12 mg produces 82.4%. A one-percentage-point gain at 12 mg in exchange for the full glucagon-class side-effect spectrum — dysesthesia at 20%, peak HR elevation, severe GI — is not the trade that makes sense for a liver-fat-primary goal. For someone optimizing hepatic outcomes, the ceiling lives at 8 mg.

1 mg retatrutide is a serious hepatic-dose signal, not just a starter dose. In the MASLD-selected substudy, the 1 mg arm produced 43% liver-fat reduction at 24 weeks — matching or exceeding much higher-dose class comparators in the local evidence base.⁷ At one-eighth the dose of retatrutide's top arm, 27% of 1 mg participants reached normal liver fat (<5%) at 24 weeks; 57% at 4 mg; 79% at 8 mg; 86% at 12 mg.

The mechanism separating retatrutide from the rest of the class: glucagon gives the liver a direct fat-burning signal. Semaglutide and tirzepatide reduce liver fat mainly through weight loss, insulin improvement, and better fat handling. Retatrutide adds a liver-facing signal on top of that. The beta-hydroxybutyrate marker, a blood sign that the liver is burning fat, rose +93% at 4 mg and +181% at 12 mg in the same trial.⁶

The liver signal appears early and reaches its ceiling before the weight-loss curve does. The 1 mg arm already moved liver fat, and 8 mg captured nearly all of the 24-week liver-fat effect. That pattern is consistent with glucagon-driven liver biology, but it is not a clean calculation of how many percentage points come from glucagon versus weight loss. Higher doses add more whole-body pressure and more side effects; they do not add much extra liver-fat reduction.

This changes the use case for retatrutide substantially. Someone with MASLD-style liver-fat concern, low-moderate BMI, and a goal of hepatic intervention without heavy appetite suppression may not need an obesity-dose mindset. For that user, 1 mg is a real hepatic-intervention signal, not merely a partial dose on the way to something stronger.

For the South Asian metabolic pattern, family history of type 2 diabetes, or other phenotypes where visceral and hepatic fat accumulate at lower BMIs than cardiovascular risk scoring assumes, this is the compound whose mechanism most directly addresses the compartment driving the risk. The question shifts from "how much weight loss do I need" to "how much liver fat do I need to mobilize" — and the dose that answers the second question is lower than the one that answers the first.

Resting energy expenditure is the open measurement. Class-comparator data from other GLP-1/glucagon drugs supports a 3–7% REE elevation at high dose, proportionally less at lower doses. Retatrutide has not published a clean direct REE measurement, so do not overstate the number. The liver-fat and ketone data show the glucagon arm is doing real hepatic work; the exact whole-body energy-expenditure magnitude remains inferred.

Side Effects Diverge Even at Matched Weight Loss

Same number on the scale, different felt experience. At each equivalence point in the four-camps table, the pharmacology producing the outcome is structurally different, and the side-effect profile follows.

Retatrutide 2 mg vs Tirzepatide 5 mg (10–13% weight loss)

Retatrutide 2 mg engages the GLP-1 receptor at roughly four times the level tirzepatide 5 mg does³ — translating to more nausea, more gastric slowing, more food aversion. Tirzepatide 5 mg sits near the upper bound of what the body naturally produces on the GLP-1 axis after a meal. Retatrutide 2 mg sits about three times above that threshold.

The glucagon arm at 2 mg is still mostly a liver story in the obesity trial frame. Heart-rate and cold-extremity signals are much smaller than at high dose, and dysesthesia is not the expected low-dose issue. Lean or highly sensitive users can still feel low doses more than the obesity trial average. Liver-fat reduction is likely meaningful, but the exact 2 mg value is projected rather than directly measured.

For someone who tolerates GI side effects poorly, tirzepatide at 5 mg is the cleaner way to reach 10–13%. For someone who wants the hepatic mechanism alongside the weight loss, or who cannot tolerate the dose volumes of tirzepatide, retatrutide at 2 mg delivers both at lower total drug burden — at the cost of more nausea during titration.

Retatrutide 5 mg vs Tirzepatide 10 mg (20% weight loss)

Same weight loss on the scale, qualitatively different side effects — and qualitatively different body composition. Retatrutide at 4 mg and above crosses the threshold where the glucagon arm starts engaging the heart's pacemaker, producing a measurable resting-heart-rate rise (a few bpm at 4 mg, 5–6 bpm at 8 mg) that fades roughly halfway from peak by 48 weeks⁴ as the body adapts to weight loss. A user who doesn't lose much weight will see less of the fade. Cold extremities can emerge subtly at this band. Tirzepatide 10 mg has no glucagon engagement at any dose; its side-effect burden is concentrated in GI and is well-characterized over multi-year exposure.

The body-composition trade is sharper than the scale numbers suggest. Phase 2 reta arms with faster titration produced slightly more weight loss than slow-ramp arms at matched maintenance, but the body-composition read there comes from waist-to-weight patterning, not DXA. Treat it as a warning signal: fast titration can push intake too low, and low intake raises the risk that some of the loss comes from lean tissue and water rather than fat. Tirzepatide's 75:25 fat-to-lean ratio in non-diabetic obesity, measured directly by DXA, is the cleaner body-composition data point — and that ratio holds across every measured subgroup.¹⁵ Retatrutide's non-diabetic body-composition signal is encouraging but still conference-level in the local corpus. Until the primary TRIUMPH-4 DXA table is available, the body-composition evidence favors tirzepatide on evidence quality.

Liver fat outcome diverges sharply in the opposite direction: retatrutide 5 mg reaches roughly 70% reduction at 24 weeks; tirzepatide 10 mg appears to sit in a lower band over the longer trial duration, mostly passive.

Retatrutide 8–12 mg vs Tirzepatide 15 mg (ceiling territory)

Tirzepatide's curve has flattened at 15 mg — that's the top, around 21% weight loss at 72 weeks with high nausea burden. Retatrutide 8 mg can reach tirzepatide-like scale loss, with the glucagon arm fully online and the hepatic mechanism near ceiling. Retatrutide 12 mg reached 24.2% in Phase 2 and 28.7% in TRIUMPH-4 topline, but at the cost of a side-effect envelope tirzepatide does not have: severe nausea in roughly half of users, the resting-heart-rate climb to about +9 bpm at 24 weeks, and burning-and-tingling sensations in the hands and feet at 12 mg in about 1 in 5 users (essentially absent on placebo).⁵

Choosing retatrutide 12 mg over tirzepatide 15 mg is buying 5–6 percentage points of weight loss with a qualitatively expanded side-effect envelope. That's a different trade than "more drug, more side effects." It's a different category of drug.

The glucagon-class side effects are not arbitrary — they're the same mechanism that produces the desirable hepatic work at low dose, scaled to peripheral tissues at high dose. Heart rate, cold fingers, sustained lipolysis, and liver fat mobilization all emerge from glucagon receptor engagement. At 1 mg the signal reaches the liver; at 8–12 mg it reaches everything else. The ceiling of the beneficial mechanism and the onset of the problematic one track the same underlying variable.

The Microdose Case

Camp 1 — the lean, metabolically minded person interested in GIP-forward benefit, hepatic work, and less appetite flattening — is where retatrutide occupies a pharmacologic space tirzepatide does not cleanly replicate.

The direct trial data: retatrutide at 1 mg weekly produced 8.7% weight loss in non-diabetic obesity and 43% liver-fat reduction at 24 weeks in the MASLD-selected substudy.⁶ ⁸ Tirzepatide at 1 mg was tested only in T2D patients — no non-diabetic 1 mg arm has ever been run — and produced 0.9 kg weight loss over 26 weeks. Projected to matched conditions (72 weeks, non-diabetic), the low-dose comparison:

The per-milligram advantage at microdose is much larger than at therapeutic dose. The mechanism is the GIP amplification plus low-dose hepatic glucagon. At 1 mg retatrutide, GIP receptor engagement is already high and the GLP-1 arm is active but moderate. The glucagon arm is doing real liver work before the full peripheral side-effect spectrum comes online. What 1 mg retatrutide delivers is meaningful metabolic work without behaving like high-dose retatrutide.

Retatrutide 0.5 mg reads differently for different bodies. In type 2 diabetes, the arm did not separate from placebo on either weight loss or HbA1c over 36 weeks⁹ — the effect floor for a desensitized incretin axis. In lower-weight or metabolically healthier users, 0.5 mg is a real microdose candidate, not just a ceremonial starter. That claim comes from trial pharmacology plus patient-generated low-dose use, not from a validated body-weight conversion. Closer to the obesity-trial population, 1 mg remains the direct evidence anchor.

For lean Asian users specifically, retatrutide's first human study saw clear pulse-rate increases at the bottom of its dose range, with the strongest early signal around days 4-6.¹³ Use that as a sensitivity warning, not as a chronic dosing forecast. A 65–73 kg lean Asian user at 0.5 mg may feel a real heart-rate signal in the first weeks even though the obesity Phase 2 cohort looked calm at 1 mg. Tirzepatide shows population shift on a different axis: Asian users plateau on tirzepatide about 2.6 weeks earlier than White users at any given dose.¹⁷ Same dose, less time before the curve flattens — useful expectation-setting at any band.

For tirzepatide, the low-dose story is different. Tirzepatide 1 mg in non-diabetic populations has not been trialed, and it is not a serious weight-loss dose. Tirzepatide 2.5 mg, however, should no longer be dismissed as inert or "only titration" in peptide-user practice. It has short-duration outcome signal and strong real-world maintenance use. It is still not the same as retatrutide microdose because it lacks the glucagon/liver-fat arm.

If the goal is hepatic or metabolic benefit at the lowest possible drug burden, retatrutide microdose has the most distinctive signal in the GLP-1 family. Below the trial's body weight, 0.25-0.5 mg may be enough for some users; closer to the trial population, 1 mg is the direct evidence anchor. If the goal is simply low-dose maintenance with a known drug, tirzepatide 2.5 mg may be the cleaner practical answer.

Switching From Tirzepatide to Retatrutide

The most common real-world switch scenario is a person on tirzepatide 10–15 mg whose weight loss has plateaued. Whether retatrutide is the right next move depends on what that "plateau" actually means.

If you are at a low baseline body weight and have normal metabolic markers, a plateau at 15 mg tirzepatide simply means you have reached the maximum utility of the GLP-1/GIP pathway. If you have severe insulin resistance (high BMI, high HbA1c), a plateau at 15 mg tirzepatide means your GIP receptors are actively resisting the signal.

In both cases, retatrutide offers additional surface area by turning on the glucagon arm — especially for liver fat, waist, and metabolic-throughput goals.

The Real-World Switching Error

Community data shows that the most common switching error is moving directly from max-dose tirzepatide (15 mg) to a high dose of retatrutide (e.g., 6–8 mg).

Users who do this frequently report achy/puffy inflammation, crushing fatigue, nausea, appetite collapse, chills, and resting-heart-rate spikes. They assume this is just "how retatrutide feels."

It is not. This is exposure whiplash. Even if your GLP-1 and GIP receptors are familiar with months of tirzepatide, your cardiovascular, thermoregulatory, and GI systems still have to adapt to retatrutide's glucagon arm.

Retatrutide's low starting doses exist to let heart rate, GI tolerance, hydration, sleep, and training adapt to a new signal. You should step down when bridging. If you switch to retatrutide and experience major heart-rate spikes, fatigue, chills, nausea, or training disruption, the correct response is usually to hold or reduce — not to push through.

What dose of retatrutide replaces my tirzepatide dose?

There is no clean replacement dose. Use this as a starting frame, not a conversion chart:

The starting frame is a tolerance test and adaptation window. The later target depends on phenotype, goal, side effects, resting heart rate, appetite, waist, glucose, and training performance.

The Bridging Protocol

The switching protocol that limits whiplash:

• Pick clean switch or cross-taper. Clean switch gives the clearest signal. Cross-taper can soften appetite rebound for high-dose tirz users, but it makes side effects harder to interpret.
• Start reta low. Lean/recomp/sensitive users often belong at 0.25-0.5 mg. Many high-dose tirz users still start around 1-2 mg, not 6-8 mg.
• Hold at least 4 weeks. Do not escalate while nausea, reflux, constipation, fatigue, chills, insomnia, skin sensitivity, elevated resting heart rate, or appetite collapse is active.
• Protect intake and training. Protein, fluids, electrolytes, bowel function, and resistance training decide whether weight loss is high quality.
• Avoid the 4 → 8 mg jump. Step through an intermediate dose if higher-dose reta is the goal.

Tirzepatide's standard titration protocol (2.5 mg starter × 4 weeks) does not translate to retatrutide. Retatrutide's dose-response is steeper at the low end — 1 mg already produces meaningful hepatic fat clearance — and the glucagon arm's peripheral effects emerge between 4 and 6 mg, requiring much slower, symptom-guided escalation.

Why people consider switching

The mechanism case for switching is strongest when the user has exhausted tirzepatide's curve or has a liver-fat / visceral-fat / recomp problem tirzepatide is not solving. Until direct head-to-head data is available, every retatrutide-vs-tirzepatide magnitude claim is an indirect comparison across different trials and populations. That is still enough to reason from; it is not enough to pretend the exact superiority number is settled.

The trade being taken on is not "more drug" — it is "different drug." A switcher who tolerates retatrutide 8 mg well may gain weight loss beyond the tirzepatide ceiling and substantially deeper liver-fat reduction. They also accept a dose-dependent heart-rate signal, more titration sensitivity, possible chills/cold extremities, and the burning-and-tingling sensations that appear at higher reta doses. Cardiac-history caveats matter more as dose rises.

Access and product quality are practical constraints. Do not let them replace the molecule comparison, but do not ignore them either.

Where the Ceilings Actually Sit

Retatrutide and tirzepatide both have ceilings. They sit in different places for different endpoints.

Tirzepatide's weight-loss ceiling is known and conclusive. The dose-response flattens above 10 mg. 15 mg adds 1.4 points over 10 mg. No trial has tested higher. Compounded vials sold at 30 mg or 60 mg are containers for sub-15 mg dosing; chronic-exposure safety data ends at 15 mg weekly, and the dose-response curve gives no efficacy reason to exceed it.

Retatrutide's weight-loss ceiling now sits above the old 25% shorthand, but the evidence is split by source. Phase 2 reached 24.2% at 48 weeks; TRIUMPH-4 topline reported 28.7% at 68 weeks. 8 mg captures most of the 12 mg Phase 2 effect, while the 8 → 12 mg step brings more of the glucagon-class side-effect spectrum online. The ceiling is higher than tirzepatide's in absolute weight loss, but the curve still flattens at the top. Doses above 12 mg are untested.

Retatrutide's liver-fat ceiling sits lower, at 8 mg. The active hepatic mechanism saturates there; 12 mg produces a 1-percentage-point gain at 24 weeks for a full glucagon-class side-effect spectrum. Anyone optimizing for hepatic outcomes specifically has no reason to exceed 8 mg.

Until direct head-to-head data is available, every claim about "retatrutide is X% better than tirzepatide" is an indirect comparison across non-matched trials. The comparison available now is good enough to decide between the two drugs for most reader scenarios, but it should be framed as mechanism plus cross-trial inference.

FAQ

Related Reading

For deep dives on each compound independently:

• Tirzepatide Guide: Dosing, Results & Side Effects — the full tirzepatide dose-response, body-composition data, and the mechanism behind the tirzepatide vs semaglutide split.
• Retatrutide: A Coherent Multi-Receptor Signal — the extended retatrutide pharmacology, receptor occupancy math, and hepatic-fat evidence.
• Microdosing Tirzepatide — where tirzepatide's microdose story actually rests.
• Retatrutide Dual-Axis Protocol — the recomp stack with tesamorelin, designed around sub-aggressive retatrutide dosing.
• Retatrutide + NAD+ Protocol — energy-support logic for the retatrutide fatigue pattern.
• GLP-1 Lean Mass Preservation — the body-composition story across semaglutide, tirzepatide, and retatrutide.
• GLP-1 Hub — broader GLP-1 family coverage.

For dose calculators: tirzepatide dosage calculator and retatrutide dosage calculator. For side-by-side compound exploration: GLP-1 comparison tool.

References

¹ Retatrutide GIP engagement vs tirzepatide — both compounds are full agonists at GIPR; once engaged, each receptor fires at native-equivalent strength. Retatrutide reaches higher GIP receptor engagement at lower doses because its GIPR binding is ~16× tighter than tirzepatide's. Primary sources: Coskun T et al. (2022) Cell Metab 34:1234–1247; Willard FS et al. (2020) JCI Insight 5:e140532.

² Tirzepatide 10 → 15 mg dose-response flattening — SURMOUNT-1 Phase 3 results, 72 weeks, BMI ≥ 27 non-diabetic. Jastreboff AM et al. (2022) N Engl J Med 387:205–216 [DOI 10.1056/NEJMoa2206038].

³ Retatrutide 2 mg vs tirzepatide 5 mg GLP-1R engagement — 13% pRO vs 3% pRO — Annex receptor occupancy tables.

⁴ Retatrutide heart-rate temporal dynamics — Jastreboff 2023 Supp Table S8 (24-hour ABPM at week 24 in non-diabetic obesity): +0.7 bpm at 1 mg, +2.2 to +4.2 bpm at 4 mg, +5.7 to +6.0 bpm at 8 mg, +9.2 bpm (95% CI 7.4 to 11.1) at 12 mg; roughly half the peak increase attenuated by week 48 across every active arm. T2D Phase 2 (Rosenstock 2023): not significantly different from dulaglutide 1.5 mg by 36 weeks. Lancet 402:529–544 [DOI 10.1016/S0140-6736(23)01053-X]; NEJM 389:514–526 [DOI 10.1056/NEJMoa2301972].

⁵ Retatrutide dysesthesia at top dose — 20.9% at 12 mg vs 0.7% placebo, 48 weeks. Jastreboff AM et al. (2023) N Engl J Med 389:514–526 [DOI 10.1056/NEJMoa2301972].

⁶ Retatrutide MASLD substudy — 98 adults with obesity + ≥10% baseline liver fat, non-diabetic, 48 weeks. 1 mg produced 43% liver fat reduction at 24 weeks; 12 mg produced 82%. β-hydroxybutyrate elevation +181% at 12 mg confirms active hepatic fatty-acid oxidation. Sanyal AJ et al. (2024) Nat Med 30:2037–2048 [DOI 10.1038/s41591-024-03018-2]; PMCID PMC11271400.

⁷ Cross-drug liver fat comparisons — tirzepatide has a ~50% placebo-adjusted non-T2D obesity MRI anchor in SURMOUNT-J and a ~47% T2D MRI anchor in SURPASS-3 MRI; semaglutide and dulaglutide comparator values appear in Sanyal 2024 discussion. Do not confuse liver-fat MRI reduction with MASH biopsy resolution.

⁸ Retatrutide 1 mg weight loss — Phase 2 obesity trial, 48 weeks, n=69, non-diabetic, treatment-regimen estimand. Jastreboff AM et al. (2023) N Engl J Med 389:514–526, NCT04881760.

⁹ Retatrutide 0.5 mg in T2D — no separation from placebo on weight or HbA1c, 36 weeks, n=46. HR dynamics: peaks early, attenuates to dulaglutide-comparable by 36 weeks. Rosenstock J et al. (2023) Lancet 402:529–544, NCT04867785.

¹⁰ Tirzepatide free-drug fraction (0.29%) and receptor occupancy math — Willard FS et al. (2020) JCI Insight 5:e140532, Table 1.

¹¹ Retatrutide receptor EC50 values — cAMP functional agonism assay. Coskun T et al. (2022) Cell Metab 34:1234–1247.

¹² Coskun 2022 mmc1 Table S1 — receptor functional activity at cAMP signaling, low-density assay, no albumin. Reta E_max at GIPR 103%, GLP-1R 110%, GCGR 104% of native peptide peak. Same paper conclusions section: "LY3437943 is a full agonist at the GCGR, GIPR, and GLP-1R in the functional assays." Earlier framings as "0.34× partial agonist at GCGR" or "0.4× softened agonist at GLP-1R" mistook potency ratios (EC50_LY ÷ EC50_native) for efficacy multipliers (E_max_LY ÷ E_max_native) and are retracted.

¹³ Coskun T et al. (2022) Cell Metab 34:1234–1247 — Phase 1 single-ascending-dose study in 45 healthy adults (NCT03841630, conducted in Singapore, ~98% Asian, mean weight 77 kg, mean BMI 26). Pulse rate eight-day average vs placebo: 0.1 mg +2.4 bpm; 0.3 mg +7.6; 1 mg +10.3; 3 mg +16.7; 4.5 mg +25.2; 6 mg +19.3. Returns toward baseline by day 29–43.

¹⁴ Retatrutide structural characterization, C20 fatty-diacid albumin anchor — Li Y et al. (2024) Cell Discov 10:77.

¹⁵ Body-composition substudy with subgroup analysis: Look M et al. (2025) Diabetes Obes Metab 27:2720 [DOI 10.1111/dom.16275]. The 75:25 fat-to-lean ratio holds across sex, age, and total-weight-loss tier subgroups (n=160 DXA substudy).

¹⁶ Real-world tirzepatide dosing patterns and outcomes — five datasets totaling more than 40,000 non-diabetic and diabetic users showing sub-10 mg dosing as the dominant maintenance pattern: Mody Diabetes Therapy 2025 (n=15,667) · Hankosky Diabetes & Metabolism 2025 (n=4,177) · Hankosky DOM 2025 (n=20,998) · Le Roux J Endocrinol Invest 2026 (n=2,396 head-to-head vs semaglutide) · Duncan Obesity Pillars 2026 (n=1,166).

¹⁷ Multivariate analysis of plateau timing on tirzepatide: Horn DB et al. (2025) Clinical Obesity 15:e12734 [DOI 10.1111/cob.12734]. Asian race users plateau ~2.6 weeks earlier than White users at any given dose, after multivariate adjustment.

Additional references: Schneck K et al. (2024) CPT Pharmacometrics Syst Pharmacol — tirzepatide population PK (n=5,802); Mounjaro and Zepbound product-label pharmacokinetic sections; network meta-analysis comparing tirzepatide and retatrutide across 12 trials (PMC12544991).

Registered trials include a direct retatrutide-vs-tirzepatide comparison in matched populations and doses (NCT06662383) and a large cardiovascular/renal outcomes trial for retatrutide (NCT06383390).